Xenon Pharmaceuticals Inc.
2 clinical trials · 2 recruiting · INDUSTRY
Trials by Xenon Pharmaceuticals Inc.
RECRUITINGPhase 3NCT05667142
A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of XEN1101 administered as...
Sponsor: Xenon Pharmaceuticals Inc.Enrolling: 16020 locations
Primary Generalized Tonic-Clonic Seizures
RECRUITINGPhase 3NCT07172516
A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder...
X-CEED is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of azetukalner in adult participants diagnosed with...
Sponsor: Xenon Pharmaceuticals Inc.Enrolling: 40020 locations
Bipolar DisorderBipolar DepressionBipolar I Disorder+1